Journal of Oncology / 2012 / Article / Tab 4

Review Article

Tumor Angiogenesis as a Target for Dietary Cancer Prevention

Table 4

Approved antiangiogenic agents and cancer indications.

Bevacizumab (Genentech/Roche)Colon, Lung, Breast, Brain, Kidney
Cetuximab (Bristol-Myers Squibb/Imclone)Colon, Head and Neck
Endostatin (Simcere)Lung
Erlotinib (Genentech/Roche/OSI)Lung, Pancreatic
Everolimus (Novartis)Kidney, Pancreatic/NET*, Brain/SEGA**
Imiquimod (Graceway/3M)Actinic keratosis, Basal cell carcinoma
Interferon alfa (Roche/Schering)Melanoma, Kaposi's sarcoma
Lenalidomide (Celgene)Myleodysplastic syndrome, Multiple myeloma
Pazopanib (GlaxoSmithKline)Kidney
Sorafenib (Bayer/Onyx)Kidney, Liver
Sunitinib (Pfizer)Kidney, GIST, Pancreatic/NET*
Temsirolimus (Wyeth)Kidney, Lymphoma
Thalidomide (Celgene)Multiple myeloma
Vandetanib (AstraZeneca)Thyroid

Available only in China.
* Neuroendocrine tumor.
** Subependymal giant cell astrocytoma, associated with tuberous sclerosis.
Source: Angiotracker, The Angiogenesis Foundation (

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.